Purpose. Hepatocellular carcinoma (HCC) is an increasingcause of mortality in HIV-infected patients inthe highly active antiretroviral therapy (HAART) era.The aims of this study were to describe HCC tumorcharacteristics and different therapeutic approaches, toevaluate patient survival time from HCC diagnosis, andto identify clinical prognostic predictors in patients withand without HIV infection.Patients and Methods. A multicenter observationalretrospective comparison of 104 HIV-infected patientsand 484 uninfected patients was performed in four Italiancenters. HCC was staged according to the BarcelonaClinic Liver Cancer (BCLC) criteria.Results. Tumor characteristics of patients with andwithout HIV were significantly different for age, EasternCooperative Oncology Group performance status(PS) score <1, and etiology of chronic liver disease. Despitethe similar potentially curative option rate and better BCLC stage at diagnosis, the median survivaltime was significantly shorter in HIV patients. HIVpatients were less frequently retreated at relapse.Independent predictors of survival were: BCLC stage,potentially effective HCC therapy, tumor dimension <3cm, HCC diagnosis under a screening program, HCC recurrence,and portal vein thrombosis. Restricting the analysisto HIV patients only, all positive prognostic factorswere confirmed together with HAART exposure.Conclusion. This study confirms a significantlyshorter survival time in HIV HCC patients. The lessaggressive retreatment at recurrence approach does notbalance the benefit of younger age and better BCLCstage and PS score of HIV patients. Thus, consideringthe prognosis of HIV HCC patients, effective screeningtechniques, programs, and specific managementguidelines are urgently needed.

Hepatocellular Carcinoma in HIV-infected Patients: Check Ealy, Treat Hard / M., Berretta; Garlassi, Elisa; B., Cacopardo; A., Cappellani; Guaraldi, Giovanni; S., Cocchi; P., de Paoli; A., Lleshi; I., Izzi; A., Torresin; P., Di Gangi; Pietrangelo, Antonello; M. C., Ferrari; A., Beraz; S., Berretta; G., Nasti; DI BENEDETTO, Fabrizio; L., Balestreri; U., Tirelli; Ventura, Paolo. - In: THE ONCOLOGIST. - ISSN 1083-7159. - STAMPA. - 16:9(2011), pp. 1258-1269. [10.1634/theoncologist.2010-0400]

Hepatocellular Carcinoma in HIV-infected Patients: Check Ealy, Treat Hard

GARLASSI, Elisa;GUARALDI, Giovanni;PIETRANGELO, Antonello;DI BENEDETTO, Fabrizio;VENTURA, Paolo
2011

Abstract

Purpose. Hepatocellular carcinoma (HCC) is an increasingcause of mortality in HIV-infected patients inthe highly active antiretroviral therapy (HAART) era.The aims of this study were to describe HCC tumorcharacteristics and different therapeutic approaches, toevaluate patient survival time from HCC diagnosis, andto identify clinical prognostic predictors in patients withand without HIV infection.Patients and Methods. A multicenter observationalretrospective comparison of 104 HIV-infected patientsand 484 uninfected patients was performed in four Italiancenters. HCC was staged according to the BarcelonaClinic Liver Cancer (BCLC) criteria.Results. Tumor characteristics of patients with andwithout HIV were significantly different for age, EasternCooperative Oncology Group performance status(PS) score <1, and etiology of chronic liver disease. Despitethe similar potentially curative option rate and better BCLC stage at diagnosis, the median survivaltime was significantly shorter in HIV patients. HIVpatients were less frequently retreated at relapse.Independent predictors of survival were: BCLC stage,potentially effective HCC therapy, tumor dimension <3cm, HCC diagnosis under a screening program, HCC recurrence,and portal vein thrombosis. Restricting the analysisto HIV patients only, all positive prognostic factorswere confirmed together with HAART exposure.Conclusion. This study confirms a significantlyshorter survival time in HIV HCC patients. The lessaggressive retreatment at recurrence approach does notbalance the benefit of younger age and better BCLCstage and PS score of HIV patients. Thus, consideringthe prognosis of HIV HCC patients, effective screeningtechniques, programs, and specific managementguidelines are urgently needed.
2011
16
9
1258
1269
Hepatocellular Carcinoma in HIV-infected Patients: Check Ealy, Treat Hard / M., Berretta; Garlassi, Elisa; B., Cacopardo; A., Cappellani; Guaraldi, Giovanni; S., Cocchi; P., de Paoli; A., Lleshi; I., Izzi; A., Torresin; P., Di Gangi; Pietrangelo, Antonello; M. C., Ferrari; A., Beraz; S., Berretta; G., Nasti; DI BENEDETTO, Fabrizio; L., Balestreri; U., Tirelli; Ventura, Paolo. - In: THE ONCOLOGIST. - ISSN 1083-7159. - STAMPA. - 16:9(2011), pp. 1258-1269. [10.1634/theoncologist.2010-0400]
M., Berretta; Garlassi, Elisa; B., Cacopardo; A., Cappellani; Guaraldi, Giovanni; S., Cocchi; P., de Paoli; A., Lleshi; I., Izzi; A., Torresin; P., Di Gangi; Pietrangelo, Antonello; M. C., Ferrari; A., Beraz; S., Berretta; G., Nasti; DI BENEDETTO, Fabrizio; L., Balestreri; U., Tirelli; Ventura, Paolo
File in questo prodotto:
File Dimensione Formato  
Hepatocellular Carcinoma in HIV-Infected Patients: Check Early, Treat Hard.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 78.8 kB
Formato Adobe PDF
78.8 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/679646
Citazioni
  • ???jsp.display-item.citation.pmc??? 39
  • Scopus 121
  • ???jsp.display-item.citation.isi??? 113
social impact